Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.
Dia A. Smiley DO
Columbia University Irving Medical Center, New York-Presbyterian Hospital
New York, NY 10019

Main Body of the Abstract
Background: Molecular imaging using PET/CT in ATTR-CA provides detailed information on the extent and quantity of systemic amyloid load, which could be valuable to track serially in the context of emerging therapies.
Objective: To quantify cardial amyloid burden on 124I-evuzamitide PET/CT, and correlate it with disease measures including NYHA class, Columbia stage, cardiac biomarkers, quality of life and functional parameters.
Methods: Myocardial uptake was measured volumetrically on static images with PMOD (Bruker, Switzerland),  using automatic iso-contouring with a threshold of mean left atrial (LA) volume of interest (VOI) activity +2 standard deviations of blood pool activity concentration. The primary left ventricle (LV) uptake metric was percent injected dose (%ID), calculated as VOI mean activity concentration x VOI volume / injected activity.  Additionally, cardiac amyloid activity (CAA) was analyzed as VOI SUVmean x VOI volume.  Correlations were quantified using Pearson’s r with 95% confidence intervals.
Results: 25 subjects were scanned; 18 had myocardial uptake on 124I-evuzamitide PET/CT (11 with ATTRv-CA and 7 with ATTRwt). There was a strong correlation between cardiac amyloid load, defined by both %ID and CAA, and high sensitivity troponin T (hs-TnT) and Columbia score. There was a moderate correlation between cardiac amyloid load and NT-proBNP level, NYHA class, KCCQ summary score, and SF36 health score.
Conclusion: Quantitation of amyloid load with I124I-evuzamitide on PET/CT correlates with direct and indirect measures of the severity of ATTR-CA, quality of life, and functional status. There was a strong correlation between cardiac amyloid load, and both Columbia score and hs-TnT.

**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Dia A. Smiley DO
Columbia University Irving Medical Center, New York-Presbyterian Hospital
New York, NY 10019

**Main Body of the Abstract**
**Background:** Molecular imaging using PET/CT in ATTR-CA provides detailed information on the extent and quantity of systemic amyloid load, which could be valuable to track serially in the context of emerging therapies.
**Objective:** To quantify cardial amyloid burden on 124I-evuzamitide PET/CT, and correlate it with disease measures including NYHA class, Columbia stage, cardiac biomarkers, quality of life and functional parameters.
**Methods**: Myocardial uptake was measured volumetrically on static images with PMOD (Bruker, Switzerland),  using automatic iso-contouring with a threshold of mean left atrial (LA) volume of interest (VOI) activity +2 standard deviations of blood pool activity concentration. The primary left ventricle (LV) uptake metric was percent injected dose (%ID), calculated as VOI mean activity concentration x VOI volume / injected activity.  Additionally, cardiac amyloid activity (CAA) was analyzed as VOI SUVmean x VOI volume.  Correlations were quantified using Pearson’s r with 95% confidence intervals.
**Results:** 25 subjects were scanned; 18 had myocardial uptake on 124I-evuzamitide PET/CT (11 with ATTRv-CA and 7 with ATTRwt). There was a strong correlation between cardiac amyloid load, defined by both %ID and CAA, and high sensitivity troponin T (hs-TnT) and Columbia score. There was a moderate correlation between cardiac amyloid load and NT-proBNP level, NYHA class, KCCQ summary score, and SF36 health score.
**Conclusion:** Quantitation of amyloid load with I124I-evuzamitide on PET/CT correlates with direct and indirect measures of the severity of ATTR-CA, quality of life, and functional status. There was a strong correlation between cardiac amyloid load, and both Columbia score and hs-TnT.

Quantitative Uptake of 124I-Evuzamitide on PET Correlates with Markers of Transthyretin Cardiac Amyloidosis, Quality of Life, and Functional Status PB135 (#506)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.